

# High Potency Active Pharmaceutical Ingredients (HPAPI)-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/H36A8E9F7A6MEN.html>

Date: May 2018

Pages: 136

Price: US\$ 3,480.00 (Single User License)

ID: H36A8E9F7A6MEN

## Abstracts

### Report Summary

High Potency Active Pharmaceutical Ingredients (HPAPI)-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on High Potency Active Pharmaceutical Ingredients (HPAPI) industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of High Potency Active Pharmaceutical Ingredients (HPAPI) 2013-2017, and development forecast 2018-2023

Main market players of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe, with company and product introduction, position in the High Potency Active Pharmaceutical Ingredients (HPAPI) market

Market status and development trend of High Potency Active Pharmaceutical Ingredients (HPAPI) by types and applications

Cost and profit status of High Potency Active Pharmaceutical Ingredients (HPAPI), and marketing status

Market growth drivers and challenges

The report segments the Europe High Potency Active Pharmaceutical Ingredients (HPAPI) market as:

Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue

and Growth Rate 2013-2023):

Germany  
United Kingdom  
France  
Italy  
Spain  
Benelux  
Russia

Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Synthetic  
Biotech

Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Synthetic  
Biotech Oncology  
Hormonal  
Glaucoma  
Others

Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market: Players Segment Analysis (Company and Product introduction, High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume, Revenue, Price and Gross Margin):

Eli Lilly and Company  
Novartis International AG  
Bristol-Myers Squibb Company  
Roche Diagnostics Limited  
Sanofi Aventis  
Hospira, Inc.  
BASF AG  
Covidien Plc

Boehringer Ingelheim GmbH  
Merck & Co., Inc.  
Sigma Aldrich Corporation  
Bayer AG  
Carbogen Amcis AG  
Lonza  
Teva Pharmaceuticals Industries Ltd.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)**

1.1 Definition of High Potency Active Pharmaceutical Ingredients (HPAPI) in This Report

1.2 Commercial Types of High Potency Active Pharmaceutical Ingredients (HPAPI)

1.2.1 Synthetic

1.2.2 Biotech

1.3 Downstream Application of High Potency Active Pharmaceutical Ingredients (HPAPI)

1.3.1 Synthetic

1.3.2 Biotech Oncology

1.3.3 Hormonal

1.3.4 Glaucoma

1.3.5 Others

1.4 Development History of High Potency Active Pharmaceutical Ingredients (HPAPI)

1.5 Market Status and Trend of High Potency Active Pharmaceutical Ingredients (HPAPI) 2013-2023

1.5.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023

1.5.2 Regional High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

2.1 Market Status of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA 2013-2017

2.2 Consumption Market of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions

2.2.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions

2.2.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions

2.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions

2.3.1 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe 2013-2017

2.3.2 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Middle East 2013-2017

2.3.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Africa 2013-2017

2.4 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA 2018-2023

2.4.1 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA 2018-2023

2.4.2 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) by Regions 2018-2023

## **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types

3.1.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Downstream Industry

4.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Major Countries

4.2.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Europe

4.2.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Middle East

4.2.3 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Africa

4.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in

EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)**

5.1 EMEA Economy Situation and Trend Overview

5.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Downstream Industry Situation and Trend Overview

## **CHAPTER 6 HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI) MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

6.1 Sales Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Major Players

6.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Major Players

6.3 Basic Information of High Potency Active Pharmaceutical Ingredients (HPAPI) by Major Players

6.3.1 Headquarters Location and Established Time of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players

6.3.2 Employees and Revenue Level of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Eli Lilly and Company

7.1.1 Company profile

7.1.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product

7.1.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Eli Lilly and Company

7.2 Novartis International AG

7.2.1 Company profile

7.2.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

## Product

7.2.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Novartis International AG

## 7.3 Bristol-Myers Squibb Company

7.3.1 Company profile

7.3.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

## Product

7.3.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

## 7.4 Roche Diagnostics Limited

7.4.1 Company profile

7.4.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

## Product

7.4.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Roche Diagnostics Limited

## 7.5 Sanofi Aventis

7.5.1 Company profile

7.5.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

## Product

7.5.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sanofi Aventis

## 7.6 Hospira, Inc.

7.6.1 Company profile

7.6.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

## Product

7.6.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Hospira, Inc.

## 7.7 BASF AG

7.7.1 Company profile

7.7.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

## Product

7.7.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of BASF AG

## 7.8 Covidien Plc

7.8.1 Company profile

7.8.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

## Product

7.8.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Covidien Plc

## 7.9 Boehringer Ingelheim GmbH

### 7.9.1 Company profile

### 7.9.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

#### Product

### 7.9.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH

## 7.10 Merck & Co., Inc.

### 7.10.1 Company profile

### 7.10.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

#### Product

### 7.10.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.

## 7.11 Sigma Aldrich Corporation

### 7.11.1 Company profile

### 7.11.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

#### Product

### 7.11.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sigma Aldrich Corporation

## 7.12 Bayer AG

### 7.12.1 Company profile

### 7.12.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

#### Product

### 7.12.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bayer AG

## 7.13 Carbogen Amcis AG

### 7.13.1 Company profile

### 7.13.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

#### Product

### 7.13.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Carbogen Amcis AG

## 7.14 Lonza

### 7.14.1 Company profile

### 7.14.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)

#### Product

### 7.14.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Lonza

## 7.15 Teva Pharmaceuticals Industries Ltd.

### 7.15.1 Company profile

### 7.15.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI)



## Product

7.15.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals Industries Ltd.

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)**

8.1 Industry Chain of High Potency Active Pharmaceutical Ingredients (HPAPI)

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)**

9.1 Cost Structure Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)

9.2 Raw Materials Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)

9.3 Labor Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)

9.4 Manufacturing Expenses Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS (HPAPI)**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: High Potency Active Pharmaceutical Ingredients (HPAPI)-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/H36A8E9F7A6MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H36A8E9F7A6MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

